1 tracked superinvestor hold GAIN THERAPEUTICS INC (GANX), worth $1M combined, led by David Einhorn. Smart money is holding GANX as of the latest 13F filings.
Current price
$1.82
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore…
Market cap
$79M
P/E
-3.08
Div yield
—
Revenue YoY
—
Analyst target
—
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$1M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding GANX steady this quarter — buys and sells are balanced.
GAIN THERAPEUTICS INC (GANX) is held by 1 tracked funds worth $1M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to David Einhorn at 0% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0% | $1M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own GANX?
1 tracked funds hold GAIN THERAPEUTICS INC (GANX), the largest being David Einhorn (Greenlight Capital) at 0% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling GANX?
In the most recent 13F quarter, 0 tracked funds added or opened GANX and 0 trimmed it.
How much GANX do tracked funds hold?
Combined disclosed long exposure to GANX across tracked superinvestors is $1M as of the Mar 2026 filings.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.